Humanizing Early Drug Discovery and Preclinical Safety Testing with Physiological iPS Cell Models

Recorded February 10, 2016

Sponsored by

Preview:

Webinar Description:

Humanizing Early Drug Discovery and Preclinical Safety Testing with Physiological iPS Cell Models. Learn how human cardiac cells, derived from induced pluripotent stem cells (iPSC), are playing a rapidly increasing role in in vitro drug discovery & development assays in the pharmaceutical industry. From high-throughput screening (HTS) to toxicology testing, human cardiac cells can be applied in pure 2D cultures for desired controls as well as 3D co-culture systems for physiological relevance. Whether you are screening for new drug targets, or investigating drug effects on electrophysiology, contractility, or cardiac-specific toxicity, this seminar will provide insights for your own research.

Learning Objectives:

Uses of iPSC-derived cell types in screening/safety applications
Humanize drug discovery/development, "Mimic Clinic"
'Real-world' examples / case studies
Axiogenesis background / overview, products/services

Speakers:

Thomas Licher, PhD

Group Leader Lead Identification Technologies (LIT) Biology

Sanofi

Andrew Bruening-Wright, PhD

Principal Scientist Discovery, Charles River

ChanTest

Ralf Kettenhofen, PhD

Head of Lab

Axiogenesis

Moderator:

Brian Murphy

Director Marketing & Sales

Axiogenesis

Click here to access